Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

by Karthick Vishwanathan, Mireille Cantarini, Karen So, Eric Masson, Jennifer Fetterolf, Suresh S. Ramalingam, R. Donald Harvey
Published 2020-01-01

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

by Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, Nidal Al‐Huniti
Published 2019-07-01

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

by Karthick Vishwanathan, Inmaculada Sanchez‐Simon, Bhumsuk Keam, Nicolas Penel, Maria deMiguel‐Luken, Doris Weilert, Andrew Mills, Marcelo Marotti, Martin Johnson, Alain Ravaud
Published 2020-08-01

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magneti...

by Simon Ekman, Zsolt Cselényi, Andrea Varrone, Aurelija Jucaite, Heather Martin, Magnus Schou, Peter Johnström, Gianluca Laus, Rolf Lewensohn, Andrew P. Brown, Jasper van derAart, Karthick Vishwanathan, Lars Farde
Published 2023-06-01